Video Endoscopy Systems in Massachusetts

Mauna Kea Technologies is a global medical device company specializing in Confocal Laser Endomicroscopy (CLE) and in vivo cellular imaging. The flagship Cellvizio® platform delivers real-time histological visualization during endoscopy procedures across gastroenterology, pulmonology, urology, and neurosurgery, enabling physicians to accelerate diagnosis, inform treatment decisions, and guide surgical interventions with cellular-level precision. FDA-cleared and CE-marked, Cellvizio has been used in over 100,000 patient procedures worldwide. The company partners with industry leaders including Johnson & Johnson and Telix Pharmaceuticals to expand therapeutic applications in precision medicine, cancer detection, and early intervention across multiple clinical specialties.

Myriad Fiber Imaging Technologies is an ISO 13485-certified medical device manufacturer specializing in ultra-precision micro-endoscopy and visualization systems. Founded in 1995, the company designs and manufactures sub-1mm diameter fiberscopes, videoscopes, and CMOS imaging endoscopes ranging from 0.37mm to 5mm in diameter. MFI offers comprehensive OEM contract manufacturing, including electronic assembly, CMOS imaging systems, optical design, image processing, CNC machining, and micro-optics assembly. The company operates an 18,000 sq ft ISO-certified facility with 30+ years of technical expertise, serving primarily the medical sector (80% of business) alongside government, aerospace, and industrial applications. MFI is a U.S. distributor of Fujikura fiber optics and OmniVision CMOS sensors, providing both high-volume production and low-volume prototyping capabilities.

Morphic Medical is a Boston-based MedTech company founded in 2003 specializing in innovative, minimally invasive device therapies for type 2 diabetes and obesity. The company's flagship product, RESET® therapy, is an endoscopically delivered device designed to address the underlying metabolic causes of type 2 diabetes and weight gain. RESET targets patients underserved by traditional pharmaceuticals and injections who are unsuitable for bariatric surgery, aiming to reduce HbA1c levels and body weight while improving glycemic control and cardiovascular risk profile. Currently investigational in the United States, RESET is undergoing clinical validation through the STEP-1 trial. Morphic Medical bridges the therapeutic gap between medical management and surgical intervention, offering a non-surgical alternative that leverages endoscopic delivery mechanisms to achieve durable metabolic benefits.

Body Vision Medical is a commercial-stage medical device company specializing in AI-powered imaging solutions for lung cancer detection and intervention. The company's flagship product, the LungVision® system, transforms standard 2D C-arm X-ray images into advanced 3D intraoperative imaging for enhanced navigation during endobronchial biopsies. Utilizing proprietary AI Tomo® technology, LungVision corrects for CT-to-body divergence and enables tool-in-lesion confirmation, improving diagnostic yield from traditional 55-75% to approximately 90-95% for small pulmonary lesions. The system delivers superior economics with lower total cost of ownership than robotic alternatives, reduced radiation exposure (1/5 of 3D C-arms), and accessibility worldwide. Founded in 2014 by engineers experienced in electromagnetic navigation bronchoscopy, Body Vision empowers pulmonologists and thoracic surgeons with real-time, high-precision navigation for biopsy and localized therapy delivery. Recognized as a Top Medtech Startup in 2023.

Boston Medical Products, Inc. is a manufacturer of ENT surgical and respiratory products, including rigid and flexible bronchoscopes, airway stents, and specialized instruments for interventional pulmonology and otorhinolaryngology. The company manufactures the original Montgomery Brand Products, developed by physicians for clinical use. Product portfolio includes DUTAU NOVATECH modular bronchoscopes, DUMON silicone airway stents, Safe-T-Tubes (standard and thoracic series), ROTEPS bronchoscopy forceps, SURVAC suction catheters, and STERITALC talc for pleurodesis procedures. The company holds FDA clearance for STERITALC (available in the US) and manufactures products compliant with international regulatory standards. Boston Medical Products provides electronic labeling (e-labelling) for product instructions for use and serves hospitals, surgical centers, and interventional pulmonology departments globally. The company is accredited by VAWD (Verbandsmaterial und Wundversorgung Distributor). Boston Medical Products is part of the bess group, which includes partnerships with international specialists such as Kurz in passive middle ear implants. Products are marketed under NOVATECH and other brand names for respiratory, ENT, and thoracic surgical applications.

Gentuity, LLC is a medical device manufacturer specializing in next-generation intravascular imaging solutions for interventional cardiology. The company's core product is the HF-OCT™ Imaging System, a high-frequency optical coherence tomography platform designed for percutaneous coronary intervention (PCI) guidance and coronary artery disease assessment. The system integrates with the Vis-Rx® PRIME Micro-Imaging Catheter, an ultra-low-profile (1.8F) device enabling access to small, tortuous, and complex coronary vessels. Key clinical capabilities include rapid full-length vessel imaging in a single pullback, saline-compatible imaging, and real-time visualization for procedural optimization. The HF-OCT system features plug-and-play integration into catheterization laboratory workflows without requiring sterile barriers. Gentuity's products target interventional cardiologists performing complex PCI procedures, with distribution partnerships including GE HealthCare (United States), Nipro Medical Europe (EMEA), and Nipro Japan. The company holds regulatory clearance documentation including Summary of Safety and Clinical Performance (SSCP) and maintains DICOM conformance standards. Marketing emphasizes clinical case studies demonstrating utility in challenging anatomies, including critically narrow lesions and calcified vessels. The company actively participates in major interventional cardiology conferences (TCT, EuroPCR, SCAI) and publishes peer-reviewed clinical evidence.

SpectraWAVE, Inc. is a medical device company specializing in innovative imaging and physiology technologies for coronary intervention. The company manufactures the HyperVue Imaging System, which combines DeepOCT+NIRS (Optical Coherence Tomography and Near-Infrared Spectroscopy) imaging with integrated physiology assessment tools. The HyperVue platform enables clinicians to acquire comprehensive coronary artery images with rapid acquisition (sub-second pullbacks with minimal or no contrast) and automated AI-powered bedside analysis to support percutaneous coronary intervention (PCI) planning and optimization. SpectraWAVE's flagship innovation is X1-FFR, a wire-free, drug-free fractional flow reserve (FFR) physiology solution that calculates FFR from a single angiogram in approximately one minute, eliminating the need for guidewires, adenosine administration, and DICOM file management delays. X1-FFR received FDA 510(k) clearance in October 2025. The integrated HyperVue with X1-FFR platform is positioned for cath labs seeking to streamline coronary diagnostics and reduce procedure time while improving treatment precision. SpectraWAVE targets interventional cardiologists and cardiac catheterization labs, offering an integrated solution that combines structural vessel assessment (DeepOCT+NIRS) with functional physiology (X1-FFR) on a single console.

Optim LLC manufactures endoscopic visualization equipment for ENT (ear, nose, throat) and functional endoscopic evaluation of swallowing (FEES) applications, along with security and industrial inspection systems. The company specializes in portable, high-quality endoscopic instruments designed for clinical use in otolaryngology and speech-language pathology practices. Primary product lines include the ENTity XL/SDXL rigid endoscopic system, the ENTity MobileFEES portable platform, flexible nasopharyngoscopes (ENT 3.6FP), rigid sinuscopes, and complementary accessories such as portable LED light sources (PLS) and USB video capture systems (VidCap). The company also manufactures security and industrial visualization equipment including the FreedomView videoscope and fiberscope systems. Optim operates a contract design and manufacturing division offering medical device design and manufacturing expertise. The company emphasizes durability, optical clarity, portability, and submersibility for complete disinfection. Manufacturing capabilities include fused fiber optics, precision optical components, and light source coupling. The company provides comprehensive customer support including service and repair, care and maintenance guidance, in-service training, and product registration programs. Optim holds GSA contract capabilities and serves healthcare providers across the United States. The company is based in Sturbridge, Massachusetts, and employs a leadership team with extensive experience in medical device manufacturing, quality assurance, optical engineering, and ENT sales.

Lumicell, Inc. is a medical technology company founded in 2009 as a spinout from MIT that specializes in fluorescence-guided imaging systems for intraoperative tumor detection and resection. The company's core platform, LumiSystem, combines LUMISIGHT (a fluorescent optical contrast agent) with the Lumicell Direct Visualization System (DVS), a handheld real-time imaging device for surgical guidance. In April 2024, both LUMISIGHT and DVS received FDA approval as the first drug-device combination approved in over a decade for this indication. The technology is designed to help surgeons identify and remove residual cancer tissue while preserving healthy tissue during breast cancer lumpectomies and other oncologic procedures. Lumicell has validated its approach in clinical studies involving over 700 breast cancer patients and is expanding applications to solid tumors including gastric and gastrointestinal cancers.

Terason, a division of Teratech Corporation, is a global leader in portable ultrasound imaging systems founded in 1994. Based in Burlington, Massachusetts, Terason pioneered the first patented color portable ultrasound and specializes in ultrasound-guided venous intervention. The company's uSmart platform delivers high-performance micro-miniaturized ultrasound systems designed for diverse clinical settings including hospitals, outpatient centers, and point-of-care environments. Key product lines include the uSmart 3300 NexGen and uSmart 3200T NexGen systems, both recognized for superior image quality and reliability across multiple medical specialties. Terason's technology portfolio features advanced capabilities such as Enhanced Needle Visualization (ENV), TeraVision II imaging, TeraScape panoramic imaging, Smart Gestures control, capacitive touch interfaces, and open architecture integration with DICOM standards. The company emphasizes comprehensive clinical education and real-time technical support through its uConnect service, alongside partnerships with major organizations like Siemens and Brainlab.

CellTivity Scientific is a medical technology company specializing in live-cell imaging platforms for real-time assessment of cellular behavior, morphology, and metabolic activity. The flagship Van Gogh Microscopy System utilizes proprietary Dynamic Cell Imaging (DCI) technology to provide non-invasive visualization of metabolic activity and tissue adequacy during biopsies. The system enables proceduralists to identify cell types—including cancer cells, immune cells, and granuloma—and assess biopsy sample quality in real time, improving diagnostic yield and reducing biopsy inadequacy. Applications span interventional pulmonology, thoracic procedures, bronchoscopy, and general tissue sampling across oncology specialties. The company offers CE-registered devices with deployment, training, and pathology integration support to hospitals and clinics, targeting enhanced point-of-care diagnostics and streamlined collaboration with pathology departments.